Status: Recruiting
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
Participants needed: 78
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Sun Pharma Japan LimitedUpdated: Jul 2, 2026Locations: 18
Eligibility criteria
Written informed consent has been obtained. [+3]
Treatment with systemic immunosuppressive medications or agents, including Janus... [+4]